ORKA
Oruka Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$96.87Close
$4.7BMarket cap
$26.19 – $113.0852-week range
Nov 11, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
Cautions
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
up 20.9%
price change
1mo
up 16.3%
price change
12-month return
up 245%
market up 11% ·
its own up 240%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
10.0×
price / book
Earnings yield
down 2.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 25%
return on equity
Free cash margin
—
-$88.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.8%
$4.65 a day · 2×ATR $87.56
RS
98 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.84
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 30.1% over the year, from 37m to 49m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026+7% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Operating income | -$9.8M | -$19.3M | -$10.6M | -$7.3M | -$88.1M | -$122.1M |
| Net income | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$83.7M | -$105.4M |
| Earnings per share | — | -$1.39 | -$0.69 | -$0.37 | -$4.99 | — |
| Free cash flow | -$7.7M | -$18.8M | -$10.9M | -$5.0M | -$58.0M | -$88.4M |
| Cash | $49.1M | $53.4M | $42.4M | $37.4M | $61.6M | $46.9M |
| Long-term debt | $0 | $0 | $0 | $0 | — | — |
| Shareholders' equity | $46.5M | $51.0M | $41.7M | $37.0M | $382.2M | $471.9M |
| Shares outstanding | 9.55m | 14.41m | 14.41m | 14.50m | 37.44m | 48.72m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 6, 2025 | Annual ↗ | Dec 31, 2024 | 65d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| Apr 25, 2024 | Quarterly ↗ | Mar 31, 2024 | 25d |
| Feb 1, 2024 | Annual ↗ | Dec 31, 2023 | 32d |
| Oct 18, 2023 | Quarterly ↗ | Sep 30, 2023 | 18d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 26, 2026 | Regulation FD · Other events ↗ |
| Aug 24, 2026 | Director or officer change ↗ |
| Aug 10, 2026 | Results ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| Jun 1, 2026 | Other events ↗ |
| Apr 30, 2026 | Results · Other events ↗ |
| Apr 27, 2026 | Regulation FD · Other events ↗ |
| Dec 11, 2025 | Director or officer change ↗ |
| Sep 22, 2025 | Material agreement · Unregistered share sale · Regulation FD ↗ |
| Jul 1, 2025 | Director or officer change ↗ |
| Jun 3, 2025 | Shareholder vote ↗ |
| Feb 5, 2025 | Material agreement ↗ |